Cargando…
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072199/ http://dx.doi.org/10.1186/2051-1426-2-S2-P18 |
| _version_ | 1782322923200053248 |
|---|---|
| author | Sylvan, S Eketorp Lundin, J Ipek, M Palma, M Karlsson, C Hansson, L |
| author_facet | Sylvan, S Eketorp Lundin, J Ipek, M Palma, M Karlsson, C Hansson, L |
| author_sort | Sylvan, S Eketorp |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4072199 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40721992014-06-27 P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients Sylvan, S Eketorp Lundin, J Ipek, M Palma, M Karlsson, C Hansson, L J Immunother Cancer Poster Presentation BioMed Central 2014-03-12 /pmc/articles/PMC4072199/ http://dx.doi.org/10.1186/2051-1426-2-S2-P18 Text en Copyright © 2014 Sylvan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Sylvan, S Eketorp Lundin, J Ipek, M Palma, M Karlsson, C Hansson, L P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients |
| title | P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients |
| title_full | P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients |
| title_fullStr | P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients |
| title_full_unstemmed | P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients |
| title_short | P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients |
| title_sort | p27. alemtuzumab (anti-cd52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (cll) – a single region experience on consecutive patients |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072199/ http://dx.doi.org/10.1186/2051-1426-2-S2-P18 |
| work_keys_str_mv | AT sylvanseketorp p27alemtuzumabanticd52monoclonalantibodyassingleagenttherapyinpatientswithrelapsedrefractorychroniclymphocyticleukaemiacllasingleregionexperienceonconsecutivepatients AT lundinj p27alemtuzumabanticd52monoclonalantibodyassingleagenttherapyinpatientswithrelapsedrefractorychroniclymphocyticleukaemiacllasingleregionexperienceonconsecutivepatients AT ipekm p27alemtuzumabanticd52monoclonalantibodyassingleagenttherapyinpatientswithrelapsedrefractorychroniclymphocyticleukaemiacllasingleregionexperienceonconsecutivepatients AT palmam p27alemtuzumabanticd52monoclonalantibodyassingleagenttherapyinpatientswithrelapsedrefractorychroniclymphocyticleukaemiacllasingleregionexperienceonconsecutivepatients AT karlssonc p27alemtuzumabanticd52monoclonalantibodyassingleagenttherapyinpatientswithrelapsedrefractorychroniclymphocyticleukaemiacllasingleregionexperienceonconsecutivepatients AT hanssonl p27alemtuzumabanticd52monoclonalantibodyassingleagenttherapyinpatientswithrelapsedrefractorychroniclymphocyticleukaemiacllasingleregionexperienceonconsecutivepatients |